European Shares Dip as Oil Surges and Novartis Slumps 8.8%

European shares edged lower as rising crude oil prices fueled renewed inflation concerns amid escalating Middle East tensions, while pharmaceutical giant Novartis tumbled following back-to-back late-stage clinical trial failures. Investors weighed the broader macroeconomic impact of expensive energy against compounding corporate disappointments across major regional indices.

"European shares dip as higher crude revives inflation worries and Novartis drags," according to a Yahoo Finance report.

By 0705 GMT on Tuesday, the pan-European STOXX 600 index was down 0.2% at 648.41 points. Regional markets showed mixed performance, as Germany's DAX shed 0.3%, London's FTSE held flat, and France's CAC 40 slipped 0.4%.

Crude Oil Prices and Inflation Pressures

Energy markets drove macroeconomic sentiment as Brent crude futures traded at $98.5 per barrel. The surge in oil prices followed threats from Iran to retaliate against new attacks by targeting energy infrastructure across the Gulf, including United States oil and gas interests.

Rising crude prices complicate the inflation outlook for European central banks, as higher energy input costs threaten to stall disinflation trends. Energy shocks directly influence transportation and manufacturing expenses across the eurozone, creating fresh headwinds for corporate profit margins and consumer purchasing power.

Novartis Trial Failures Drag Healthcare Sector

Corporate developments compounded market losses, led by a sharp selloff in pharmaceutical heavyweight Novartis. Novartis shares tumbled 8.8% after the company reported that late-stage testing of del-desiran for myotonic dystrophy failed to meet its primary endpoint.

The setback followed another negative announcement on Monday regarding its experimental cholesterol drug pelacarsen, which also failed to deliver positive results in a late-stage trial. These consecutive clinical failures wiped billions off the drugmaker's market valuation and weighed heavily on the broader European healthcare sector.

Sandoz Counterbalances Sector Sentiment

Amid the broader healthcare slump, spin-off firm Sandoz bucked the trend by adding 2.9%. The Swiss generic drug manufacturer gained ground after stating it aims to more than double its net sales from 2025 to 2035, offering investors a rare bright spot in an otherwise defensive trading session.